Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.67 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8592674 | 1.00 | TAAR1 (0.67) | TAAR1IDO1AGXTADRB2TSHR | |
| SCHEMBL27528330 | 0.88 | TAAR1 (0.70) | TAAR1IDO1AGXTADRB2CHRM2 | |
| SCHEMBL13006639 | 0.84 | TAAR1 (0.69) | TAAR1IDO1AGXTADRB2CHRM2 | |
| SCHEMBL9810888 | 0.84 | TAAR1 (0.47) | TAAR1ADRB2TSHRMAPK1 | |
| SCHEMBL9810853 | 0.83 | PTGES (0.50) | TAAR1TSHR | |
| SCHEMBL7510495 | 0.83 | TAAR1 (0.62) | TAAR1IDO1AGXTADRB2TSHR | |
| SCHEMBL7510484 | 0.83 | TAAR1 (0.62) | TAAR1IDO1AGXTADRB2TSHR | |
| SCHEMBL9781361 | 0.83 | TAAR1 (0.72) | TAAR1IDO1AGXTADRB2CHRM2 | |
| SCHEMBL9071087 | 0.82 | TAAR1 (0.71) | TAAR1IDO1AGXTADRB2CHRM2 | |
| SCHEMBL29365903 | 0.82 | TAAR1 (0.71) | TAAR1IDO1AGXTADRB2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TAAR1 685/4885IDO1 1700/4885AGXT 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.